Related Experiment Video
Updated: Jan 25, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
Published on: June 27, 2025
Cathepsin S promotes the development of pulmonary arterial hypertension
Chi-Jen Chang1, Hsiu-Chi Hsu2,3, Wan-Jing Ho1
1Cardiovascular Division, Chang Gung Memorial Hospital , Taoyuan , Taiwan.
Insights
Cathepsin S (Cat S) drives pulmonary arterial hypertension (PAH) by degrading elastic fibers. Inhibiting Cat S with Millipore-219393 and stimulating PPARγ offers a potential treatment for PAH.
Area of Science:
- Cardiovascular Research
- Molecular Biology
- Pathophysiology
Background:
- Cysteine cathepsin proteases are crucial in cardiovascular disease and extracellular matrix (ECM) degradation.
- Pulmonary arterial hypertension (PAH) involves increased elastase in pulmonary arterial smooth muscle cells (PASMCs), linked to ECM remodeling.
Purpose of the Study:
- To investigate the role of cathepsin proteases in PASMC proliferation and ECM regulation in PAH.
- To test the hypothesis that cathepsin proteases in PASMCs promote PAH development.
Main Methods:
- Examined cathepsin S (Cat S) expression and elastic laminae degradation in human PAH lungs and a rat model (MCT-PAH).
- Administered a selective Cat S inhibitor (Millipore-219393) to MCT-PAH rats.
- Utilized small interfering RNA (siRNA) to reduce Cat S or PPARγ expression in human PASMCs.
Main Results:
- Overexpression of Cat S and elastic laminae degradation were observed in PAH lungs and MCT-PAH rat PASMCs.
- Cat S inhibition in MCT-PAH rats suppressed PASMC proliferation and migration.
- PPARγ stimulation by the Cat S inhibitor was identified as a key mechanism.
- PPARγ was found to be upstream of Cat S signaling.
Conclusions:
- Cathepsin S activity significantly contributes to pulmonary vascular remodeling and elastin fiber degradation in PAH.
- The interplay between Cat S and PPARγ is pathophysiologically important in PAH.
- Targeting Cat S and modulating PPARγ presents a potential therapeutic strategy for PAH.
Abstract:
Cysteine cathepsin proteases play critical roles in cardiovascular disease progression and are implicated in extracellular matrix (ECM) degradation. Patients with pulmonary arterial hypertension (PAH) exhibit increased elastase production by pulmonary arterial smooth muscle cells (PASMCs), which is related to the degradation of elastic fibers and pulmonary vascular remodeling. However, the mechanism by which cathepsins regulate the ECM and PASMC proliferation in PAH remains unclear. We hypothesized that cathepsin proteases in PASMCs promote the development of PAH. Here, we show overexpression of cathepsin S (Cat S) and degradation of elastic laminae in the lungs of patients with idiopathic PAH and in the PASMCs of monocrotaline-induced PAH model (MCT-PAH) rats. In addition, pulmonary hypertension can be treated in MCT-PAH rats by administering a selective Cat S inhibitor, Millipore-219393, which stimulates peroxisome proliferator-activated receptor-γ (PPARγ) to inhibit the expression of Cat S, thus suppressing the proliferation and migration of MCT-PAH PASMCs. We then reduced Cat S or PPARγ expression by using small interfering RNA in human PASMCs to demonstrate a mechanistic link between Cat S signaling and PPARγ protein, and the results suggest that PPARγ is upstream of Cat S signaling. In conclusion, the activity of Cat S in pulmonary vascular remodeling and degradation of elastin fibers through the disruption of PPARγ is pathophysiologically significant in PAH.
More Related Videos
Related Concept Videos
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pulmonary Hypertension: Classification and Pathogenesis
There are various classifications for PH, each relating to different underlying causes and also...

